A clinical double-blind trial comparing amorolfine cream 0.5% (RO-14-4767) with bifonazole cream 1% in the treatment of dermatomycoses
- 1 March 1989
- journal article
- clinical trial
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 14 (2) , 141-144
- https://doi.org/10.1111/j.1365-2230.1989.tb00912.x
Abstract
In a double-blind parallel study, 40 patients with dermatomycoses (one cutaneous candidosis and 39 dermatophyte infections) were treated topically with amorolfine (RO-14-4767) cream (0.5%), a new antifungal compound, or with bifonazole cream (1%). The treatment was applied once daily and was continued until 1 week after resolution of the symptoms, the maximum duration of treatment was limited to 6 weeks. Assessment of results was based on both clinical and mycological parameters. The percentages of amorolfine- and bifonazole-treated patients who were clinically and mycologically cured were 83.33% and 78.95%, respectively. Two patients treated with amorolfine and one patient treated with bifonazole were withdrawn from the trial because of side-effects. There was no significant difference between the two creams in clinical and mycological cure rates and tolerance.Keywords
This publication has 1 reference indexed in Scilit:
- Antifungal activityin vitroof Ro 14-4767/002, a phenylpropyl-morpholineMedical Mycology, 1983